' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

OPPERMANN KATRIN
Universitätsklinik für Neurologie

Publikationen | Forscherprofil

36 Publikationen

2017

Beiträge in Fachzeitschriften

From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Harrer, A; Pilz, G; Oppermann, K; Sageder, M; Afazel, S; Haschke-Becher, E; Rispens, T; de Vries, A; McCoy, M; Stevanovic, V; Hitzl, W; Trinka, E; Kraus, J; Sellner, J; Wipfler, P;
Clin Immunol. 2017; 176: 87-93.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Automated brain tissue and lesion segmentation in multiple sclerosis: A feasibility study in the state of Salzburg
Varosanec, M; Marschallinger, R; Karamyan, A; Sellner, J; Oppermann, K; Golaszewski, SM; Wipfler, P; McCoy, MR; Trinka, E
EUR J NEUROL. 2017; 24: 429-430.
Abstracts (Zeitschrift)

2016

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Evidence of gender differences for initiation of therapy escalation in multiple sclerosis
Karamyan, A; Oppermann, K; Bacher, C; Otto, F; Pilz, G; Wipfler, P; Chroust, V; Sellner, J
MULT SCLER J. 2016; 22: 723-723.
Abstracts (Zeitschrift)
Prevalence and predictors of sexual dysfunction in multiple sclerosis: a cross-sectional study
Otto, F; Bacher, C; Chroust, V; Karamyan, A; Oppermann, K; Reisp, M; Pilz, G; Wipfler, P; Sellner, J
MULT SCLER J. 2016; 22: 727-727.
Abstracts (Zeitschrift)

2015

Beiträge in Fachzeitschriften

High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Harrer, A; Pilz, G; Wipfler, P; Oppermann, K; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J;
Clin Exp Immunol. 2015; 180(3):383-392
Originalarbeiten (Zeitschrift)
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer, A; Wipfler, P; Pilz, G; Oppermann, K; Haschke-Becher, E; Afazel, S; Kraus, J; Trinka, E; Sellner, J;
Int J Mol Sci. 2015; 16(9): 21832-21845.
Originalarbeiten (Zeitschrift)

2014

Beiträge in Fachzeitschriften

A routine-qualified flow cytometric method for the identification of multiple sclerosis patients with reduced therapy efficiency under natalizumab
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Sellner, J; Deisenhammer, F; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2014; 38(1): 17-23.
Originalarbeiten (Zeitschrift)
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Sellner, J; Trinka, E; Kraus, J;
Acta Neurol Scand. 2014; 129(3):e12-e15
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Natalizumab and fingolimod differentially impact the alpha-4/beta-1 and alpha-L/beta-2 expression-related subset diversity of T-cells
Harrer, A; Oppermann, K; Wanek, J; Pilz, G; Wipfler, P; Sellner, J; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2014; 20: 333-333.
Abstracts (Zeitschrift)

2013

Beiträge in Fachzeitschriften

Tumefactive MS lesions under fingolimod: a case report and literature review.
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Fazekas, F; Trinka, E; Kraus, J;
Neurology. 2013; 81(19): 1654-1658.
Originalarbeiten (Zeitschrift)
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner, J; Koczi, W; Harrer, A; Oppermann, K; Obregon-Castrillo, E; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clin Exp Immunol. 2013; 173(3):381-389
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Shift in the CD4+/CD8+ratio of cerebrospinal fluid T cells independent from free or cell-bound natalizumab
Harrer, A; Oppermann, K; Pizl, G; Wipfler, P; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 451-452.
Abstracts (Zeitschrift)
Flow-cytometry and the detection of natalizumab-neutralizing antibodies in multiple sclerosis
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Holl, B; Deisenhammer, F; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 500-501.
Abstracts (Zeitschrift)

2012

Beiträge in Fachzeitschriften

Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy.
Broussalis, E; Hutterer, M; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Haschke-Becher, E; Golaszewski, S; Schönauer, U; Weis, S; Killer-Oberpfalzer, M; Mc Coy, M; Trinka, E; Kraus, J;
Acta Neurol Scand. 2012; 126(3):e11-e16
Fallberichte
Flow cytometry and drug monitoring of natalizumab saturation of immune cells in multiple sclerosis
Harrer, A; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, L; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 377-382.
Originalarbeiten (Zeitschrift)
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Hitzl, W; Wipfler, P; Sellner, J; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
PLoS One. 2012; 7(2):e31784
Originalarbeiten (Zeitschrift)
Overview of laboratory methods to monitor innovative treatment regimens in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Holl, B; Oppermann, K; Golaszewski, SM; Harrer, A
LABORATORIUMSMEDIZIN. 2012; 36(6): 389-396.
Übersichtsarbeiten
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz, G; Harrer, A; Oppermann, K; Wipfler, P; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Mult Scler. 2012; 18(4):506-509
Originalarbeiten (Zeitschrift)
Future relevance of CSF biomarkers in modern MS treatment
Pilz, G; Wipfler, P; Harrer, A; Holl, B; Oppermann, K; Golaszewski, SM; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 383-388.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Natalizumab Treatment Effects Sustained Decrease in Serum Levels of Fibronectin and Soluble Adhesion Molecules sVCAM-1 and sICAM-3
Kraus, J; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A
NEUROLOGY. 2012; 78:
Abstracts (Zeitschrift)
Serum Levels of Soluble Adhesion Molecules Remain Stable during Short- and Long-Term Interferon-beta-1b Treatment
Kraus, J; Zaunrieth, R; Obregon-Castrillo, E; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Golaszewski, S; Hitzl, W; Trinka, E; Harrer, A
NEUROLOGY. 2012; 78:
Abstracts (Zeitschrift)

2011

Beiträge in Fachzeitschriften

Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer, A; Wipfler, P; Einhaeupl, M; Pilz, G; Oppermann, K; Hitzl, W; Afazel, S; Haschke-Becher, E; Strasser, P; Trinka, E; Kraus, J;
J Neuroimmunol. 2011; 234(1-2):148-154
Originalarbeiten (Zeitschrift)
Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Trinka, E; Kraus, J;
Drug Discov Today. 2011; 16(1-2):8-21
Übersichtsarbeiten
Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J;
Mult Scler. 2011; 17(1):16-23
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Natalizumab binding to peripheral blood mononuclear cells analysed by flow cytometry can be used for monitoring treatment response in patients with multiple sclerosis
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Wipfler, P; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
J NEUROL. 2011; 258: 13-14.
Abstracts (Zeitschrift)
Anti-Inflammatory Effects of Copaxone on the Level of Adhesion Molecule Expression Patterns during Short- and Long-Term Treatment
Kraus, J; Oppermann, K; Harrer, A; Koczi, W; Duerr, EM; Wipfler, P; Pilz, G; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E
NEUROLOGY. 2011; 76(9): A384-A384.
Abstracts (Zeitschrift)
Flow Cytometry of Natalizumab Binding to Immune Cells and Its Potential Use for Monitoring Disease Activity and Treatment Response in Patients with Multiple Sclerosis
Kraus, J; Pilz, G; Einhaeupl, M; Oppermann, K; Wipfler, P; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A
NEUROLOGY. 2011; 76(9): A135-A136.
Abstracts (Zeitschrift)
Copaxone treatment shows anti-inflammatory effects on the level of adhesion molecule expression on peripheral blood mononuclear cells during short- and long-term therapy
Oppermann, K; Harrer, A; Koczi, W; Duerr, E; Wipfler, P; Pilz, G; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
J NEUROL. 2011; 258: 206-206.
Abstracts (Zeitschrift)

2010

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections
Kraus, J; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Afazel, S; Haschke-Becher, E; Kunz, AB; Golaszewski, SM; Staffen, W; Ladurner, G
NEUROLOGY. 2010; 74(9): A416-A416.
Abstracts (Zeitschrift)
Short- and long-term decrease of soluble adhesion molecules (sICAM-1,-2,-3 and sVCAM-1) during natalizumab treatment
Oppermann, K; Pilz, G; Wipfler, P; Harrer, A; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S220-S220.
Abstracts (Zeitschrift)
Expression levels of cell surface bound interferon-receptor remain stable during short- and long-term interferon beta-1b treatment
Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Duerr, EM; Koczi, W; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S219-S219.
Abstracts (Zeitschrift)
Accumulation of natalizumab at the VLA-4 receptor as a potential molecular basis of enhanced treatment efficacy and occurrence of opportunistic infections
Wipfler, P; Oppermann, K; Pilz, G; Harrer, A; Haschke-Becher, E; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S8-S8.
Abstracts (Zeitschrift)

2009

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Short-term decrease of soluble adhesion molecules during natalizumab treatment
Oppermann, K; Pilz, G; Wipfler, P; Sulzer, C; Afazel, S; Haschke-Becher, E; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S133-S133.
Abstracts (Zeitschrift)
Therapeutic effect of natalizumab despite the presence of neutralising antibodies shown by cell surface bound alpha4-integrin expression
Pilz, G; Wipfler, P; Oppermann, K; Sulzer, C; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S133-S133.
Abstracts (Zeitschrift)
Natalizumab Treatment Leads to Changes in Adhesion Molecule Expression
Wipfler, P; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Huemer, M; Jakab, M; Ritter, M; Ladurner, G; Kraus, J
NEUROLOGY. 2009; 72(11): A37-A38.
Abstracts (Zeitschrift)
Long-term effect of natalizumab on cell surface bound adhesion molecules expression
Wipfler, P; Pilz, G; Oppermann, K; Afazel, S; Huemer, M; Haschke-Becher, E; Staffen, W; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S195-S196.
Abstracts (Zeitschrift)